General Mills seen as a soft buy despite revenue decline and risks from new drugs and private labels.

General Mills is rated a soft buy due to its attractive valuation after a prolonged decline, despite recent underperformance. The company faces challenges from GLP-1 appetite-suppressing drugs and growing private label popularity, which threaten its revenue and brand strength. While it shows strong net income margins and a high dividend yield, concerns remain over a 6.5% year-over-year revenue decline, shrinking earnings per share, and significant current liabilities. Investors may consider this a potential bottoming opportunity but should watch for sustainability risks.